Euronext Paris

CommScope Completes Divestiture of Home Networks Business to Vantiva

Retrieved on: 
Tuesday, January 9, 2024

CommScope (NASDAQ: COMM), a global leader in network connectivity, announced today the closing of the transaction to sell its Home Networks Business to Vantiva (Euronext Paris: VANTI.)

Key Points: 
  • CommScope (NASDAQ: COMM), a global leader in network connectivity, announced today the closing of the transaction to sell its Home Networks Business to Vantiva (Euronext Paris: VANTI.)
  • The Company previously announced the signing of a definitive agreement for the transaction on October 3, 2023.
  • The Company expects the impact of the divestiture to be immaterial to its adjusted EBITDA on a full-year basis.
  • CommScope and the CommScope logo are registered trademarks of CommScope and/or its affiliates in the U.S. and other countries.

Ekinops' 2023 revenue: €129.1 million, up 1%

Retrieved on: 
Wednesday, January 10, 2024

Sequentially, Q4 sales were up +9% compared with Q3 2023, which was the lowest point of the year.

Key Points: 
  • Sequentially, Q4 sales were up +9% compared with Q3 2023, which was the lowest point of the year.
  • Ekinops' consolidated FY 2023 revenue came to 129.1m€, up +1% Y-o-Y.
  • Share of Software & Services at 17% of FY 2023 revenue, up +12%
    The contribution of Software & Services continued to increase, to stand at 17% of Group's FY 2023 revenue, compared with 15% a year earlier.
  • The region represented 25% of the Group's revenue in FY 2023 (vs. 23% a year earlier and 18% in 2021).

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Monday, January 8, 2024

Based on promising data obtained in the Phase I[*] trial ( NCT04183166 ), Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024.

Key Points: 
  • Based on promising data obtained in the Phase I[*] trial ( NCT04183166 ), Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024.
  • Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.
  • We are looking forward to continuing to treat patients in our clinical studies with our individualized cancer vaccine TG4050.
  • Our joint clinical development plan builds on these promising data in a setting where there is no approved treatment to prevent patient relapse after adjuvant chemoradiotherapy.

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

Retrieved on: 
Thursday, January 4, 2024

Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San Francisco and virtually at the Oddo BHF Forum on January 15,2024.

Key Points: 
  • Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8 – 10, 2024 in San Francisco and virtually at the Oddo BHF Forum on January 15,2024.
  • Valneva’s CEO and CFO will notably discuss the Company’s advanced vaccine development pipeline, including its Lyme disease vaccine candidate VLA15 (Phase 3 fully enrolled, partnered with Pfizer), as well as the Company’s growing commercial business, which now includes recently FDA-approved1 IXCHIQ®, the world’s first licensed vaccine for prevention of disease caused by chikungunya virus, launching in early 2024.
  • To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can

EQS-News: Abivax 2024 Financial Communication Calendar

Retrieved on: 
Thursday, January 4, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.
  • 2023 Annual Business and Financial Report (as of December 31, 2023)
    2024 Half-Year Business and Financial Report (as of June 30, 2024)
    Third Quarter 2024 Financial Information (as of September 30, 2024)

Abivax 2024 Financial Communication Calendar

Retrieved on: 
Thursday, January 4, 2024

PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.

Key Points: 
  • PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar.
  • 2023 Annual Business and Financial Report (as of December 31, 2023)
    2024 Half-Year Business and Financial Report (as of June 30, 2024)
    Third Quarter 2024 Financial Information (as of September 30, 2024)

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

Retrieved on: 
Thursday, January 4, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.
  • On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death in the TELLOMAK study.
  • The FDA decision to lift the partial clinical hold is based on the FDA review of the fatal case which Innate, together with a steering committee of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.
  • “We have worked closely with the FDA to diligently resolve the partial clinical hold on the lacutamab IND, which included an in-depth analysis of the fatal case which was due to progression of an aggressive form of the disease,” said Dr Quaratino, Chief Medical Officer of Innate Pharma.

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Retrieved on: 
Thursday, January 4, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
  • Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board.
  • Arvind Sood joins the Company in a newly created position of Executive Vice President, Innate Pharma SA and President of US Operations.
  • “We are taking steps to position Innate Pharma for future success by significantly strengthening our Executive Board now comprising Yannis, Sonia and Arvind,” said Hervé Brailly, interim Chief Executive Officer.

TaTaTu S.p.A.: TERMINATION OF THE LIQUIDITY CONTRACT DATED 09/22/2022 WITH EXANE AND IMPLEMENTATION OF A NEW CONTRACT OF LIQUIDITY WITH KEPLER CHEUVREUX

Retrieved on: 
Wednesday, January 3, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Tatau S.p.A, and Kepler Cheuvreux (the “New Liquidity Provider”) have signed on December 21, 2023 a liquidity contract regarding the liquidity of Tatatu S.p.A shares admitted to Euronext Paris (the “Agreement”).
  • The implementation of the Agreement will be carried out in accordance with the legal provisions in force, and more specifically with the provisions of Regulation (EU) No.
  • This press release and the corporate events calendar are available on the Company's website at the following address https://corporate.tatatu.com/en/corporate/ Investors section/Financial Calendar.

Technicolor Creative Studios: Listing suspension

Retrieved on: 
Tuesday, January 2, 2024

Following the expiry of the simplified tender offer on its shares, Technicolor Creative Studios SA has requested the suspension of the listing of its shares on Euronext Paris with effect from the date hereof until implementation of the squeeze-out.

Key Points: 

Following the expiry of the simplified tender offer on its shares, Technicolor Creative Studios SA has requested the suspension of the listing of its shares on Euronext Paris with effect from the date hereof until implementation of the squeeze-out.